Announcement on Voluntary Disclosure of the Latest Data of Suvozertinib as First-Line Treatment for EGFR PACC or Other Rare Mutant Non-Small Cell Lung Cancer Released at the 2026 European Lung Cancer Conference (ELCC)
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment